Israel & Middle East · raised · Biotech / Healthcare
A 41-patient Parkinson's trial produced motor score gains of 9.7 points on the MDS-UPDRS scale against 1.95 points for levodopa controls.
Remepy pairs prescription digital protocols with existing drugs to form hybrid treatments. A 41-patient Parkinson's Phase IIa trial produced motor gains of 9.7 points on the MDS-UPDRS scale versus 1.95 for levodopa alone. Merck KGaA's venture arm led its $36 million Series A.